Navigation Links
Relmada Therapeutics to Participate in BIO CEO and Investor Conference
Date:2/13/2017

NEW YORK, Feb. 13, 2017 /PRNewswire/ -- Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, today announced that the company will participate in the BIO CEO and Investor Conference to be held February 13-14, 2017 at the Waldorf Astoria in New York City.

Sergio Traversa, chief executive officer of Relmada, is scheduled to present on Tuesday, February 14th at 10:30am ET in the Conrad presentation room.

Continue Reading
Sergio Traversa, CEO of Relmada Therapeutics
Sergio Traversa, CEO of Relmada Therapeutics

The BIO CEO and Investor Conference is focused on established and emerging publicly traded and select private biotech companies. For more information, visit https://www.bio.org/events/bio-ceo-investor-conference.

A live webcast of the presentation will be available through the Company's website at www.relmada.com. Please register at least 10 minutes prior to the start of the presentation to ensure timely access. The webcast and presentation will also be archived on the website for 90 days after the conference.

About Relmada Therapeutics, Inc.

Relmada Therapeutics is a clinical-stage, publicly traded biotechnology company developing novel versions of proven drug products together with new chemical entities that potentially address areas of high unmet medical need in the treatment of central nervous system (CNS) diseases. The Company has a diversified portfolio of four products at various stages of development, including d-Methadone (dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist for depression and neuropathic pain; LevoCap ER (REL-1015), an abuse resistant, sustained release dosage form of the opioid analgesic levorphanol; oral buprenorphine (BuTab, REL-1028), an oral dosage form of the opioid analgesic buprenorphine; and topical mepivacaine (MepiGel, REL-1021), an orphan drug designated topical formulation of the local anesthetic mepivacaine. The Company's product development efforts are guided by the internationally recognized scientific expertise of its research team. The Company's approach is expected to reduce clinical development risks and costs while potentially delivering valuable products to address areas of high unmet medical needs. For more information, please visit Relmada's website at: www.relmada.com.  

Forward-Looking Statements

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by us or on our behalf. We may from time to time make written or oral statements in this letter, the proxy statements filed with the SEC communications to stockholders and press releases which constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based upon management's current expectations, estimates, assumptions and beliefs concerning future events and conditions and may discuss, among other things, anticipated future performance, expected product development, product potential, future business plans and costs. Any statement that is not historical in nature is a forward-looking statement and may be identified by the use of words and phrases such as "expects," "anticipates," "believes," "will," "will likely result," "will continue," "plans to" and similar expressions. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Relmada undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Readers are cautioned that it is not possible to predict or identify all of the risks, uncertainties and other factors that may affect future results and that the risks described herein should not be considered to be a complete list.

Contact

Investor Contact:
Michael Becker, Chief Financial Officer
Relmada Therapeutics Inc.
Tel: 646-677-3857
mbecker@relmada.com

Media Contact:
Lynn Granito
Berry & Company Public Relations
Tel: 212-253-8881
lgranito@berrypr.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/relmada-therapeutics-to-participate-in-bio-ceo-and-investor-conference-300406088.html


'/>"/>
SOURCE Relmada Therapeutics, Inc.
Copyright©2017 PR Newswire.
All rights reserved


Related biology technology :

1. Relmada Therapeutics Inc. Completes $8.0 Million Capital Raise In Series A Financing
2. Relmada Therapeutics Announces Results of Annual Shareholders Meeting
3. Edison Initiates Coverage on Relmada Therapeutics
4. Relmada Therapeutics Announces Reverse Stock Split in Preparation for Proposed Uplisting to NASDAQ Capital Market
5. Relmada Therapeutics to Provide an Update on the Development Plan for LevoCap ER
6. Peptide Therapeutics Market is Expected to Reach USD 25.4 Billion Globally in 2018: Transparency Market Research
7. Novira Therapeutics Completes $25 Million Series A Financing
8. Biovista und DART Therapeutics nehmen Zusammenarbeit auf, um auf Duchenne-Muskeldystrophie abzielende Medikamente neu zu positionieren
9. Aratana Therapeutics Adds To Drug Development Team
10. Galectin Therapeutics Reports Full Year and Fourth Quarter 2012 Financial Results
11. Galectin Therapeutics: Turning Atlanta into Americas Next Silicon Valley
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/9/2019)... (PRWEB) , ... July 08, 2019 , ... Today, at ... Iowa, the National Corn Growers Association (NCGA) announced the winners of the ... improve a product or process using field corn to produce biobased materials. , “Corn ...
(Date:7/2/2019)... Calif. (PRWEB) , ... July 02, 2019 , ... Leading ... documentary entitled Animal Pharm: Where Beasts Meet Biotech. The film focuses on regenerative ... wild animals. Animal Pharm was recently included in the Brentwood and ...
(Date:6/18/2019)... ... June 17, 2019 , ... ... entered into an agreement for production and manufacturing of GMP-grade adeno-associated virus (AAV) ... rhodopsin-mediated autosomal dominant retinitis pigmentosa (RHO-adRP) and IC-200 for the treatment of BEST1 ...
(Date:6/12/2019)... HARBOR TOWNSHIP, N.J. (PRWEB) , ... June 12, ... ... manufacturer of custom built, helium-based leak testing instruments for the Pharmaceutical, Biotechnology, Medical ... agreement with Shanghai Zillion has been signed. The agreement will grant exclusive rights ...
Breaking Biology Technology:
(Date:7/17/2019)... ... July 16, 2019 , ... Imagine using a simple, portable test to ... before it causes osteoporosis. For South Dakota School of Mines & Technology researcher Congzhou ... in terms of our ability to monitor and prevent disease,” says Wang. , ...
(Date:7/9/2019)... ... July 09, 2019 , ... Murrieta ... into its incubator program. The founder and CEO of Tx Genetic, Helen Harrison, ... of those suffering from epithelial connective tissue disorders. , “We are pleased and ...
(Date:7/5/2019)... ... July 05, 2019 , ... ... bring its patented Tractus™ Platform to governments around the world. , Powered ... technology and point of care solutions to operating theatres worldwide to address new ...
Breaking Biology News(10 mins):